317 related articles for article (PubMed ID: 31751770)
1. Reduced-Toxicity (BuFlu) Conditioning Is Better Tolerated but Has a Higher Second Transplantation Rate Compared to Myeloablative Conditioning (BuCy) in Children with Inherited Metabolic Disorders.
Gupta A; Downey M; Shanley R; Jennissen C; Miller WP; Lund TC; Orchard PJ; Smith AR
Biol Blood Marrow Transplant; 2020 Mar; 26(3):486-492. PubMed ID: 31751770
[TBL] [Abstract][Full Text] [Related]
2. Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine.
Harris AC; Boelens JJ; Ahn KW; Fei M; Abraham A; Artz A; Dvorak C; Frangoul H; Freytes C; Gale RP; Hong S; Lazarus HM; Loren A; Mineishi S; Nishihori T; O'Brien T; Williams K; Pasquini MC; Levine JE
Blood Adv; 2018 Jun; 2(11):1198-1206. PubMed ID: 29844205
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine.
Lee JH; Joo YD; Kim H; Ryoo HM; Kim MK; Lee GW; Lee JH; Lee WS; Park JH; Bae SH; Hyun MS; Kim DY; Kim SD; Min YJ; Lee KH
J Clin Oncol; 2013 Feb; 31(6):701-9. PubMed ID: 23129746
[TBL] [Abstract][Full Text] [Related]
4. Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study.
Liu H; Zhai X; Song Z; Sun J; Xiao Y; Nie D; Zhang Y; Huang F; Zhou H; Fan Z; Tu S; Li Y; Guo X; Yu G; Liu Q
J Hematol Oncol; 2013 Feb; 6():15. PubMed ID: 23394705
[TBL] [Abstract][Full Text] [Related]
5. Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial.
Ling Y; Xuan L; Xu N; Huang F; Fan Z; Guo Z; Xu X; Liu H; Lin R; Yu S; Zhang H; Jin H; Wu M; Liu C; Liang X; Ou R; Zhang Y; Liu X; Qu H; Zhai X; Sun J; Zhao Y; Liu Q
J Clin Oncol; 2023 Oct; 41(29):4632-4642. PubMed ID: 37335960
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Different Conditioning Regimens of Haploidentical Hematopoietic Stem Cell Transplant in Patients With Acute Myeloid Leukemia.
Jiang Y; Fang X; Sui X; Liu X; Li Y; Wang X; Xu H; Zhang L; Wang X
Exp Clin Transplant; 2018 Dec; 16(6):736-744. PubMed ID: 29790457
[TBL] [Abstract][Full Text] [Related]
7. Feasibility of non-TBI conditioning with busulfan and fludarabine for allogeneic stem cell transplantation in lymphoid malignancy.
Shin HC; Lee YJ; Moon JH; Lee SJ; Kang BW; Chae YS; Kim JG; Choi JY; Seo JW; Kim YK; Suh JS; Sohn SK
Korean J Intern Med; 2012 Mar; 27(1):72-83. PubMed ID: 22403503
[TBL] [Abstract][Full Text] [Related]
8. Busulfan plus fludarabine compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with hematologic neoplasms: a meta-analysis.
Lei XR; Chen HL; Wang FX; Bai J; He AL
Int J Clin Exp Med; 2015; 8(8):12064-75. PubMed ID: 26550118
[TBL] [Abstract][Full Text] [Related]
9. Tolerability and efficacy of busulfan and fludarabine as allogeneic pretransplant conditioning therapy in acute myeloid leukemia: comparison with busulfan and cyclophosphamide regimen.
Fedele R; Messina G; Martinello T; Gallo GA; Pontari A; Moscato T; Console G; Dattola A; Princi D; Cuzzola M; Alati C; Ronco F; Molica S; Irrera G; Martino M
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):493-500. PubMed ID: 25034142
[TBL] [Abstract][Full Text] [Related]
10. Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia.
Saraceni F; Beohou E; Labopin M; Arcese W; Bonifazi F; Stepensky P; Aljurf M; Bruno B; Pioltelli P; Passweg J; Sociè G; Santarone S; Yakoub-Agha I; Lanza F; Savani BN; Mohty M; Nagler A;
Am J Hematol; 2018 Oct; 93(10):1211-1219. PubMed ID: 30033639
[TBL] [Abstract][Full Text] [Related]
11. Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
Ji YS; Lee MS; Min CW; Park SK; Kim SH; Yun J; Kim HJ; Kim KH; Kim CK; Lee KT; Won JH; Hong DS
Korean J Intern Med; 2016 Jul; 31(4):750-61. PubMed ID: 27017944
[TBL] [Abstract][Full Text] [Related]
12. Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity.
Bartelink IH; van Reij EM; Gerhardt CE; van Maarseveen EM; de Wildt A; Versluys B; Lindemans CA; Bierings MB; Boelens JJ
Biol Blood Marrow Transplant; 2014 Mar; 20(3):345-53. PubMed ID: 24315842
[TBL] [Abstract][Full Text] [Related]
13. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
[TBL] [Abstract][Full Text] [Related]
14. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
[TBL] [Abstract][Full Text] [Related]
15. Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma.
Ayala E; Figueroa J; Perkins J; Kim J; Yue B; Riches M; Nishihori T; Locke F; Anasetti C; Kharfan-Dabaja MA
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):335-40. PubMed ID: 25659459
[TBL] [Abstract][Full Text] [Related]
16. Busulfan and cyclophosphamide-based conditioning regimen still holds the promise of being a safe and efficacious regimen for allogeneic transplantation in patients with transfusion-dependent thalassemia, even in high risk.
Mehta P; Kapoor J; Singh A; Yadav N; Singh R; Halder R; Verma M; Agrawal N; Ahmed R; Bhurani D
Eur J Haematol; 2022 Nov; 109(5):447-457. PubMed ID: 35781894
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens.
Maymani H; Lin P; Saliba RM; Popat U; Bashir Q; Shah N; Patel K; Parmar S; Kebriaei P; Hosing C; Ciurea S; Andersson B; Shpall E; Champlin R; Srour SA; Qazilbash MH
Biol Blood Marrow Transplant; 2019 May; 25(5):1039-1044. PubMed ID: 30639822
[TBL] [Abstract][Full Text] [Related]
18. Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies.
Pasquini MC; Le-Rademacher J; Zhu X; Artz A; DiPersio J; Fernandez HF; Mineishi S; Kamishohara M; Mehta J; Nakamura Y; Ratanatharathorn V; Sobecks R; Burkart J; Bredeson C
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1424-1430. PubMed ID: 27154848
[TBL] [Abstract][Full Text] [Related]
19. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
[TBL] [Abstract][Full Text] [Related]
20. A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen.
Satwani P; Bhatia M; Garvin JH; George D; Dela Cruz F; Le Gall J; Jin Z; Schwartz J; Duffy D; van de Ven C; Foley S; Hawks R; Morris E; Baxter-Lowe LA; Cairo MS
Biol Blood Marrow Transplant; 2012 Feb; 18(2):324-9. PubMed ID: 22079471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
